Last reviewed · How we verify

tacrolimus OD, mycophenolic acid, prednisolone

University Medical Center Groningen · FDA-approved active Small molecule

tacrolimus OD, mycophenolic acid, prednisolone is a Immunosuppressive combination therapy Small molecule drug developed by University Medical Center Groningen. It is currently FDA-approved for Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas), Maintenance immunosuppression post-transplantation. Also known as: advagraf, mycophenolic acid.

This triple immunosuppressive regimen suppresses T-cell activation and proliferation to prevent organ rejection after transplantation.

This triple immunosuppressive regimen suppresses T-cell activation and proliferation to prevent organ rejection after transplantation. Used for Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas), Maintenance immunosuppression post-transplantation.

At a glance

Generic nametacrolimus OD, mycophenolic acid, prednisolone
Also known asadvagraf, mycophenolic acid
SponsorUniversity Medical Center Groningen
Drug classImmunosuppressive combination therapy
TargetCalcineurin (tacrolimus); IMPDH (mycophenolic acid); glucocorticoid receptor (prednisolone)
ModalitySmall molecule
Therapeutic areaImmunology / Transplantation
PhaseFDA-approved

Mechanism of action

Tacrolimus inhibits calcineurin and blocks T-cell receptor signaling; mycophenolic acid inhibits inosine monophosphate dehydrogenase to reduce lymphocyte proliferation; prednisolone is a corticosteroid that broadly suppresses immune cell activation and cytokine production. Together, these agents provide complementary immunosuppression to prevent allograft rejection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about tacrolimus OD, mycophenolic acid, prednisolone

What is tacrolimus OD, mycophenolic acid, prednisolone?

tacrolimus OD, mycophenolic acid, prednisolone is a Immunosuppressive combination therapy drug developed by University Medical Center Groningen, indicated for Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas), Maintenance immunosuppression post-transplantation.

How does tacrolimus OD, mycophenolic acid, prednisolone work?

This triple immunosuppressive regimen suppresses T-cell activation and proliferation to prevent organ rejection after transplantation.

What is tacrolimus OD, mycophenolic acid, prednisolone used for?

tacrolimus OD, mycophenolic acid, prednisolone is indicated for Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas), Maintenance immunosuppression post-transplantation.

Who makes tacrolimus OD, mycophenolic acid, prednisolone?

tacrolimus OD, mycophenolic acid, prednisolone is developed and marketed by University Medical Center Groningen (see full University Medical Center Groningen pipeline at /company/university-medical-center-groningen).

Is tacrolimus OD, mycophenolic acid, prednisolone also known as anything else?

tacrolimus OD, mycophenolic acid, prednisolone is also known as advagraf, mycophenolic acid.

What drug class is tacrolimus OD, mycophenolic acid, prednisolone in?

tacrolimus OD, mycophenolic acid, prednisolone belongs to the Immunosuppressive combination therapy class. See all Immunosuppressive combination therapy drugs at /class/immunosuppressive-combination-therapy.

What development phase is tacrolimus OD, mycophenolic acid, prednisolone in?

tacrolimus OD, mycophenolic acid, prednisolone is FDA-approved (marketed).

What are the side effects of tacrolimus OD, mycophenolic acid, prednisolone?

Common side effects of tacrolimus OD, mycophenolic acid, prednisolone include Nephrotoxicity, Neurotoxicity (tremor, headache), Hyperglycemia, Hypertension, Gastrointestinal disturbances, Infections.

What does tacrolimus OD, mycophenolic acid, prednisolone target?

tacrolimus OD, mycophenolic acid, prednisolone targets Calcineurin (tacrolimus); IMPDH (mycophenolic acid); glucocorticoid receptor (prednisolone) and is a Immunosuppressive combination therapy.

Related